Phase 2

Results of LOTIS-2, a multicenter, open-label, single-arm Phase II clinical trial evaluating the safety and efficacy of single-agent loncastuximab tesirine-lpyl (Zynlonta™; ADC Therapeutics; previously...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Gilead Sciences* Sacituzumab Govitecan** (Trodelvy®) for use in adult patients with locally...

Each year more than 13,500 women in the United States are diagnosed with invasive cervical cancer and approximately 4,200 will die of the disease....

This week a first patient was dosed in DESTINY-CRC02 (NCT04744831), a global phase II clinical trial evaluating the efficacy and safety of trastuzumab deruxtecan...

Astellas Pharma and Seagen have confirmed that the companies have completed the submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food...

Genmab and Seagen have submitted a Biologics Licence Application or BLA to the U.S. Food and Drug Administration (FDA) for tisotumab vedotin. The companies are...

MORAb-202, Eisai’s first antibody-drug conjugate, targets FRα-positive solid tumors. The investigational agent is composed of the company’s in-house developed anticancer agent farletuzumab, a humanized...

Enrolment for the pivotal Phase II clinical trial (NCT04052997) evaluating the efficacy and safety of camidanlumab tesirine (formerly ADCT-301) in patients with relapsed or...

A novel ROR1-targeted antibody-drug conjugate (ADC), zilovertamab vedotin, also known as  MK-2140 or VLS-101, has demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402. The investigational agent is...